Clinical trials: Breathing
Snoring, Sleep Apnea, Obstructive
Efficacy of Intra-oral Neuromuscular Stimulation Training on Snoring and Mild Sleep Apnoea
It has been shown that a common cause for snoring and throat obstruction (obstructive sleep apnoea (OSA)) is excessive loss of muscle tone in the throat when the investigators go to sleep.
- Trial name
- NCT04392765
- Testing
- eXciteOSA
- Where
- 6 sites in Canada, Germany and 2 more
- Volunteers
- 200 people
- Sponsor
- Signifier Medical Technologies
Asthma
Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients
This study will investigate the effect of dosing with flutucasone furoate in asthmatic subjects aged 5-11 years of age. A randomized, two-way crossover, with placebo control, over a 14 day treatment period, it will investigate…
- Trial name
- NCT01332292
- Testing
- Fluticasone furoate
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus
This randomized, multicenter, open-label, active-comparator, 2-arm, parallel-group, 6 month study with approximately 360 patients will compare the efficacy of two treatment regimens (Algorithm A versus Algorithm B) in…
- Trial name
- NCT00391209
- Testing
- simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
- Where
- 42 sites in United States, Argentina and 7 more
- Volunteers
- 379 people
- Sponsor
- Eli Lilly and Company
Central Sleep Apnea, Heart Failure
Prospective Evaluation of Heart Failure Patients With Central Sleep Apnea
Central sleep apnea (CSA) has been associated with increased mortality and primarily occurs in patients with heart failure (HF).
- Trial name
- NCT01414309
- Where
- 4 sites in United States, Germany
- Volunteers
- 5 people
- Sponsor
- Respicardia, Inc.
Asthma
Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids
To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.
- Trial name
- NCT01090024
- Testing
- BI 671800
- Where
- 14 sites in United States
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy
To assess the comparative effectiveness of combination Tiotropium and Olodaterol (Tio+Olo) (FDC) compared to combination LAMA/LABA and ICS (fixed or open), and to explore whether this varies across COPD sub populations defined by…
- Trial name
- NCT04184297
- Testing
- Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
- Where
- United States
- Volunteers
- 27,190 people
- Sponsor
- Boehringer Ingelheim
Respiratory Depression
ENA-001 for Opioid Induced Respiratory Depression
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.
- Trial name
- NCT06967259
- Testing
- ENA-001
- Where
- 2 sites in United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Enalare Therapeutics Inc.
Chronic Obstructive Pulmonary Disease
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The ability for patients with COPD to exercise is limited due to the deterioration of their lung function. NVA237 is being developed to treat COPD.
- Trial name
- GLOW3 (NCT01154127)
- Testing
- NVA237
- Where
- 10 sites in United States, Germany and 3 more
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
This open-label study will evaluate the safety of continued therapy with inhaled treprostinil in participants who have completed Study RIN-PH-304 (NCT03496623).
- Trial name
- PERFECT OLE (NCT03794583)
- Testing
- Inhaled treprostinil solution
- Where
- 32 sites in United States, Israel and 1 more
- Volunteers
- 41 people
- Sponsor
- United Therapeutics
Asthma, Allergy
ATEM (Alvesco Non-interventional Study)
The aim of the study is to evaluate the efficacy of Alvesco in patients with persistent asthma including or excluding allergic components over 3 months, especially in the spring season.
- Trial name
- ATEM (NCT01147224)
- Testing
- Alvesco
- Where
- 79 sites in Austria
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
This is a multi-center, randomized, double-blind, parallel-group study. The FF/VI inhalation powder once daily and VI inhalation powder once daily will be evaluated in subjects with COPD over 156 weeks.
- Trial name
- NCT01957150
- Testing
- Fluticasone Furoate/Vilanterol, Vilanterol
- Where
- 45 sites in United States, Canada and 3 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431274
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 239 sites in United States, Argentina and 23 more
- Volunteers
- 2,624 people
- Sponsor
- Boehringer Ingelheim
Obstructive Sleep Apnea
Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)
The purpose of this clinical trial is to demonstrate long-term safety and efficacy of the Inspire system. The Inspire Upper Airway Stimulation (UAS) therapy is intended to treat moderate-to-severe obstructive sleep apnea by…
- Trial name
- STAR (NCT01161420)
- Testing
- Inspire Upper Airway Stimulation System
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 929 people
- Sponsor
- Inspire Medical Systems, Inc.
Asthma
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in comparison to a Placebo-HFA control MDI and the…
- Trial name
- NCT01357642
- Testing
- Epinephrine inhalation aerosol
- Where
- 33 sites in United States
- Volunteers
- 373 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Diabetes, Diabetes Mellitus, Type 2
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin or rosiglitazone treatment, both in combination with metformin and glimepiride.
- Trial name
- NCT00427154
- Testing
- rosiglitazone, inhaled human insulin, metformin
- Where
- 103 sites in United States
- Volunteers
- 227 people
- Sponsor
- Novo Nordisk A/S
Pulmonary Disease, Chronic Obstructive
Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will be the first administration of CCI15106 capsules for inhalation to humans. The primary objective of the study is to investigate the safety and tolerability of single and repeat escalating doses of CCI15106 in…
- Trial name
- NCT03243760
- Testing
- CCI15106 7.5 mg capsule
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Oncology
The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects
An exploratory open label study to improve the function and welfare of late-stage solid cancer subjects (with or without lung involvement) who failed or refused anti-cancer treatment by ACC treatment, administered orally and…
- Trial name
- ONCO-004-1 (NCT03582280)
- Testing
- Amorphous Calcium Carbonate (ACC) - Amor
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Amorphical Ltd.
Diabetes Mellitus, Type 1
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
This study is being done to find out the good and bad effects of a drug that is not approved for sale and the effects if any on measures of pulmonary function in adult males and females with type 1 diabetes mellitus.
- Trial name
- NCT00137046
- Testing
- Subcutaneous Insulin, Inhaled Insulin
- Where
- 73 sites in United States, Argentina and 3 more
- Volunteers
- 582 people
- Sponsor
- Pfizer
Non-cystic Fibrosis Bronchiectasis
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
- Trial name
- iBEST-1 (NCT02712983)
- Testing
- TIP
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Apnea - Obstructive
A Study of the Sleepnet Elara APAP Device
The goal of this study is to evaluate the effectiveness of the Elara APAP device.
- Trial name
- NCT07559708
- Testing
- Sleepnet Elara Treatment
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sleepnet Corporation